ClinicalTrials.gg

Program

Esomeprazole

Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.

Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.

Furthest: phase 4, since Sep 12, 2005122 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca920 open or runningphase 4since Sep 12, 2005Mar 16, 2004none ahead
Hanmi Pharmaceutical50 open or runningphase 3since Sep 4, 2019Dec 8, 2017none ahead
Aralez Pharmaceuticals40 open or runningphase 1since Jan 11, 2008Jan 11, 2008none ahead
Chong Kun Dang Pharmaceutical30 open or runningphase 1since Feb 6, 2018Feb 6, 2018none ahead
Pfizer30 open or runningphase 4since Jan 21, 2016Feb 25, 2012none ahead
Takeda30 open or runningphase 2since Apr 14, 2016Jul 16, 2009none ahead
Torrent Pharmaceuticals30 open or runningphase 1since Nov 9, 2015Nov 9, 2015none ahead
EMS20 open or runningphase 4since Sep 2, 2015Sep 2, 2015none ahead
Elpen Pharmaceutical10 open or runningphase 4since Nov 7, 2016Nov 7, 2016none ahead
Eurofarma Laboratorios10 open or runningphase 3since Oct 31, 2011Oct 31, 2011none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Sep 6, 2021Sep 6, 2021none ahead
HALEON10 open or runningphase 1since Feb 22, 2022Feb 22, 2022none ahead
Johnson & Johnson10 open or runningphase 4since Apr 20, 2007Apr 20, 2007none ahead
Joincare Pharmaceutical Group Industry11 open or runningphase 3since Feb 7, 2025Feb 7, 2025none ahead
SD Biosensor10 open or runningphase 4since Jan 19, 2009Jan 19, 2009none ahead

Also a collaborator on its studies: iqvia-rds-inc, laboratory-corporation-of-america, medidata-solutions, thermo-fisher-scientific-inc, ciscrp, arvinas-estrogen-receptor-inc, parexel and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since May 8, 2008.

  1. Dec 8, 2017Hanmi Pharmaceutical's first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT03372850 · 96 enrolled · Korea, Republic of
  2. Feb 6, 2018Chong Kun Dang Pharmaceutical's first study: phase 1 study in Gastroesophageal RefluxNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03444402 · 18 enrolled · Korea, Republic of
  3. Apr 5, 2018Phase 3 study in Esophagitis, PepticAstraZeneca · NCT03553563 · 50 enrolled · Japan
  4. Jun 1, 2018Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT03558425 · 41 enrolled · Korea, Republic of
  5. Mar 18, 2019Phase 1 study in Heathy VolunteerHanmi Pharmaceutical · NCT03882112 · 24 enrolled · Korea, Republic of
  6. Sep 4, 2019Phase 3 study in Erosive Gastroesophageal Reflux DiseaseHanmi Pharmaceutical · NCT04080726 · 213 enrolled · Korea, Republic of
  7. Dec 17, 2019Phase 1 study in Healthy VolunteerHanmi Pharmaceutical · NCT04204629 · 25 enrolled · Korea, Republic of
  8. Mar 26, 2020Phase 3 study in Non-erosive Gastroesphageal Reflux DiseaseHanmi Pharmaceutical · NCT04325620 · 208 enrolled · Korea, Republic of
  9. Jan 7, 2021Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT04703374 · 48 enrolled · Korea, Republic of
  10. Sep 6, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05038969 · 30 enrolled · Egypt
  11. Jan 31, 2022Phase 3 study in Gastroesophageal RefluxAstraZeneca · NCT05267613 · 53 enrolled · United States, Argentina, Australia and more
  12. Feb 22, 2022HALEON's first study: phase 1 study in Gastrointestinal DiseasesNew to HALEONHALEON · NCT05265247 · 61 enrolled · Canada
  13. Feb 16, 2024Phase 1 study in HealthyPfizer · NCT06275841 · 12 enrolled · United States
  14. Feb 7, 2025Joincare Pharmaceutical Group Industry's first study: phase 3 study in Esophagitis, PepticNew to Joincare Pharmaceutical Group IndustryJoincare Pharmaceutical Group Industry · NCT06850480 · 356 planned · China

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

The newest 60 of 122 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06850480Esophagitis, Peptic · China3RecruitingJoincare Pharmaceutical Group IndustryApr 15, 2025356
NCT06275841Healthy · United States1CompletedPfizerMay 3, 202412
NCT05265247Gastrointestinal Diseases · Canada1CompletedHALEONJun 2, 202261
NCT05267613Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedAstraZenecaAug 10, 202653
NCT05038969Healthy · Egypt1CompletedGenuine Research Center, EgyptApr 1, 202130
NCT04703374Gastroesophageal Reflux · Korea, Republic of1UNKNOWNChong Kun Dang PharmaceuticalSep 202148
NCT04325620Non-erosive Gastroesphageal Reflux Disease · Korea, Republic of3CompletedHanmi PharmaceuticalAug 3, 2020208
NCT04204629Healthy Volunteer · Korea, Republic of1CompletedHanmi PharmaceuticalFeb 20, 202025
NCT04080726Erosive Gastroesophageal Reflux Disease · Korea, Republic of3CompletedHanmi PharmaceuticalDec 3, 2019213
NCT03882112Heathy Volunteer · Korea, Republic of1CompletedHanmi PharmaceuticalAug 28, 201924
NCT03558425Gastroesophageal Reflux · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalSep 14, 201841
NCT03553563Esophagitis, Peptic · Japan3CompletedAstraZenecaDec 27, 202250
NCT03444402Gastroesophageal Reflux · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalMay 4, 201818
NCT03372850Healthy · Korea, Republic of1UNKNOWNHanmi PharmaceuticalJun 15, 201896
NCT03083639Healthy Participants · United States1CompletedTakedaMay 13, 201752
NCT02959255Helicobacter Pylori Infection · Greece4CompletedElpen PharmaceuticalDec 30, 2017364
NCT02743949Gastroesophageal Reflux · Belgium, Bulgaria, Czechia and more2CompletedTakedaOct 5, 2018256
NCT02680132Healthy1CompletedTorrent PharmaceuticalsMay 201156
NCT02680119Healthy1CompletedTorrent PharmaceuticalsMay 201156
NCT02708355Heartburn · United States4CompletedPfizerApr 201655
NCT02670642Gastroesophageal Reflux · Austria, France, Germany and more3CompletedAstraZenecaNov 2002877
NCT02624544Psoriasis4WithdrawnEMSJan 20160
NCT02659683Healthy Subjects1CompletedTorrent PharmaceuticalsMay 201154
NCT02552641Helicobacter Pylori Infection · Brazil4WithdrawnEMSFeb 20160
NCT02153398Stomach Ulcer · Japan3CompletedAstraZenecaApr 201655
NCT02157376Gastrointestinal Hemorrhage · China3CompletedAstraZenecaFeb 2016343
NCT01964131Stomach Ulcer · Japan1CompletedAstraZenecaDec 201334
NCT01757275Peptic Ulcer Hemorrhage · China3CompletedAstraZenecaDec 2014239
NCT01669811Esophagitis, Peptic · Japan3CompletedAstraZenecaMay 20141,398
NCT01595425Bioequivalence Study · Japan1CompletedAstraZenecaJun 201271
NCT01549574Healthy · Belgium1CompletedPfizerMay 201216
NCT01494402Bioequivalence Study · Japan1CompletedAstraZenecaMar 201277
NCT01471925Gastroesophageal Reflux · Brazil3WithdrawnEurofarma Laboratorios0
NCT01397084Gastroesophageal Reflux4CompletedAstraZenecaJan 2012107
NCT01370538Heartburn · United States3CompletedAstraZenecaOct 2011341
NCT01370525Heartburn · United States3CompletedAstraZenecaOct 2011340
NCT01358383Arthritis, Juvenile · United States1CompletedAstraZenecaJun 201128
NCT01249651Heartburn · China4CompletedAstraZenecaJun 2011101
NCT01210339Cardiovascular Diseases · Sweden1CompletedAstraZenecaAug 201158
NCT01199328Peptic Ulcer · United States1CompletedAstraZenecaNov 201034
NCT01163630Effect of Food · United States1CompletedAstraZenecaSep 201024
NCT01159145Pharmacodynamics Study · Japan1CompletedAstraZenecaSep 201042
NCT01119768Non-Erosive Reflux Disease · China4CompletedAstraZenecaJun 2011305
NCT01094483Platelet Inhibition · United States1CompletedAstraZenecaMay 201040
NCT01069939Stomach Ulcer · Japan, Korea, Republic of, Taiwan3CompletedAstraZenecaNov 2011427
NCT01015729Peptic Ulcer · Canada1TerminatedAstraZeneca30
NCT00998075Peptic Ulcer · Canada1CompletedAstraZenecaDec 2009138
NCT00992381Healthy · Australia1CompletedAstraZeneca24
NCT00942175Stomach Ulcer · United States1CompletedTakedaJun 2010160
NCT00930215Healthy · Japan1CompletedAstraZeneca48
NCT00907400Healthy · Sweden1CompletedAstraZenecaSep 200948
NCT00825630Helicobacter Pylori Infection · Israel4CompletedSD BiosensorNov 2009123
NCT00761501Healthy Volunteer · Sweden1CompletedAstraZenecaDec 200838
NCT00734097Gastroesophageal Reflux · Argentina, Chile, Colombia and more4CompletedAstraZenecaOct 2008314
NCT00692055Arthritis · United States1CompletedAralez PharmaceuticalsJul 200830
NCT00688428Ulcer1CompletedAstraZenecaApr 200884
NCT00687245Gastroesophageal Reflux1CompletedAstraZenecaMay 200840
NCT00684190Gastroesophageal Reflux · Sweden1CompletedAstraZenecaJun 200830
NCT00676442Arthritis · United States1CompletedAralez PharmaceuticalsJun 200824
NCT00676117Healthy · Japan1CompletedAstraZenecaJul 200830

How it is read

Names in the registry

  • “Esomeprazole”, 72 entries
  • “esomeprazole”, 8 entries
  • “PN400”, 8 entries
  • “Esomeprazole (Nexium)”, 3 entries
  • “HIP1601”, 3 entries

Codes read as this program: D961H, D026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.